Search research articles
Contact Us
Filters
Showing results (161-170 of 259) with videos related to
Page
of 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 24, 2008
Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study
Evandro de Azambuja, Marianne Paesmans, Marc Beauduin, et al.
ESMO Open
|
November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
Matteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
The New England Journal of Medicine
|
June 6, 2017
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, et al.
International Journal of Cancer
|
November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
Matteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.
Anticancer Research
|
February 4, 2019
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial
Amir Sonnenblick, Andrew Bailey, Beatrice Uziely, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2015
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
Ciara C O'Sullivan, Ian Bradbury, Christine Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2019
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
Isabelle Gingras, Eileen Holmes, Evandro De Azambuja, et al.
Breast Cancer Research and Treatment
|
November 8, 2023
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
Diogo Martins-Branco, Marie Kassapian, Véronique Debien, et al.
British Journal of Cancer
|
March 24, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
Daniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, et al.
Page
of 26
Search research articles
Search
Showing results (161-170 of 259) with videos related to
Sort By:
Page
of 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 24, 2008
Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study
Evandro de Azambuja, Marianne Paesmans, Marc Beauduin, et al.
ESMO Open
|
November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
Matteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
The New England Journal of Medicine
|
June 6, 2017
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, et al.
International Journal of Cancer
|
November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
Matteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.
Anticancer Research
|
February 4, 2019
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial
Amir Sonnenblick, Andrew Bailey, Beatrice Uziely, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2015
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
Ciara C O'Sullivan, Ian Bradbury, Christine Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2019
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
Isabelle Gingras, Eileen Holmes, Evandro De Azambuja, et al.
Breast Cancer Research and Treatment
|
November 8, 2023
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
Diogo Martins-Branco, Marie Kassapian, Véronique Debien, et al.
British Journal of Cancer
|
March 24, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
Daniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, et al.
Page
of 26